BRPI0716647A2 - processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1 - Google Patents

processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1

Info

Publication number
BRPI0716647A2
BRPI0716647A2 BRPI0716647A BRPI0716647A BRPI0716647A2 BR PI0716647 A2 BRPI0716647 A2 BR PI0716647A2 BR PI0716647 A BRPI0716647 A BR PI0716647A BR PI0716647 A BRPI0716647 A BR PI0716647A BR PI0716647 A2 BRPI0716647 A2 BR PI0716647A2
Authority
BR
Brazil
Prior art keywords
antibodies
multiple myeloma
combination therapies
treatment processes
therapies based
Prior art date
Application number
BRPI0716647A
Other languages
English (en)
Portuguese (pt)
Inventor
Afar Daniel
c anderson Kenneth
Tai Yu-Tzu
Original Assignee
Dana Farber Cancer Inst Inc
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0716647(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc, Pdl Biopharma Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BRPI0716647A2 publication Critical patent/BRPI0716647A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
BRPI0716647A 2006-08-07 2007-08-07 processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1 BRPI0716647A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
BRPI0716647A2 true BRPI0716647A2 (pt) 2017-05-16

Family

ID=38831279

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716647A BRPI0716647A2 (pt) 2006-08-07 2007-08-07 processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1

Country Status (23)

Country Link
US (4) US8632772B2 (show.php)
EP (5) EP2641600A1 (show.php)
JP (1) JP5340935B2 (show.php)
CN (1) CN101686971B (show.php)
AU (1) AU2007281684C1 (show.php)
BR (1) BRPI0716647A2 (show.php)
CA (1) CA2660356C (show.php)
CY (5) CY1116247T1 (show.php)
DK (2) DK2641601T3 (show.php)
ES (2) ES2589302T3 (show.php)
HR (2) HRP20150449T1 (show.php)
HU (4) HUE029027T2 (show.php)
IL (2) IL196919A (show.php)
LT (4) LT2641601T (show.php)
LU (3) LU93276I2 (show.php)
MX (1) MX2009001441A (show.php)
NL (1) NL300840I2 (show.php)
NO (1) NO346835B1 (show.php)
NZ (1) NZ574978A (show.php)
PL (2) PL2641601T3 (show.php)
PT (2) PT2641601T (show.php)
SI (2) SI2641601T1 (show.php)
WO (1) WO2008019378A1 (show.php)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641600A1 (en) 2006-08-07 2013-09-25 AbbVie Biotherapeutics Inc. Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies
DK2068930T3 (da) 2006-08-07 2012-10-29 Abbott Biotherapeutics Corp Sammensætninger og fremgangsmåder under anvendelse af anti-CS1-antistoffer til at behandle multiple myelomer
CA2726804C (en) * 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
KR20110028450A (ko) 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
EP3090737A1 (en) * 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
ES2502541T3 (es) 2009-09-10 2014-10-03 Kyowa Hakko Kirin Co., Ltd. Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4)
US8841325B2 (en) * 2009-11-24 2014-09-23 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP3066128B1 (en) * 2013-11-06 2018-10-31 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
NZ717673A (en) 2013-11-21 2020-02-28 Hoffmann La Roche Anti-alpha-synuclein antibodies and methods of use
HRP20230265T1 (hr) * 2014-08-22 2023-04-14 Celgene Corporation Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
EA201791049A1 (ru) * 2014-12-04 2017-10-31 Бристол-Майерс Сквибб Компани Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
AU2016260895B2 (en) 2015-05-13 2021-08-05 Morphosys Ag Treatment for multiple myeloma (MM)
DK3313528T3 (da) * 2015-06-29 2021-09-20 Bristol Myers Squibb Co Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer
CN105688185B (zh) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2018182529A1 (en) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anti oligosaccharide antibody
CN111373246A (zh) * 2017-11-22 2020-07-03 希成生物医药 包括硼替佐米的聚合物纳米颗粒
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN115298549A (zh) 2019-11-05 2022-11-04 百时美施贵宝公司 M蛋白测定及其用途
CN115368462B (zh) * 2022-07-19 2026-01-02 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
WO1996037208A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
KR100822149B1 (ko) * 2002-05-17 2008-04-15 셀진 코포레이션 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
JP2008519028A (ja) * 2004-11-04 2008-06-05 フィブロン リミテッド Ｂ細胞悪性腫瘍の治療
EP2641600A1 (en) 2006-08-07 2013-09-25 AbbVie Biotherapeutics Inc. Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies
DK2068930T3 (da) 2006-08-07 2012-10-29 Abbott Biotherapeutics Corp Sammensætninger og fremgangsmåder under anvendelse af anti-CS1-antistoffer til at behandle multiple myelomer
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

Also Published As

Publication number Publication date
ES2535437T3 (es) 2015-05-11
IL196919A (en) 2016-03-31
CY2016037I1 (el) 2017-07-12
HUE029027T2 (en) 2017-01-30
LT2641601T (lt) 2016-10-10
AU2007281684C1 (en) 2013-12-19
IL196919A0 (en) 2009-11-18
NO20090968L (no) 2009-04-30
LU93275I2 (fr) 2016-12-27
EP3115049A1 (en) 2017-01-11
US8632772B2 (en) 2014-01-21
PL2068874T3 (pl) 2015-06-30
EP2068874A1 (en) 2009-06-17
MX2009001441A (es) 2009-07-06
US20160137735A1 (en) 2016-05-19
CY1117992T1 (el) 2017-05-17
CY2016038I1 (el) 2017-07-12
EP2068874B1 (en) 2015-01-28
SI2068874T1 (sl) 2015-06-30
HK1129853A1 (en) 2009-12-11
JP5340935B2 (ja) 2013-11-13
CY1116247T1 (el) 2017-02-08
HUS1600043I1 (hu) 2016-12-28
US20170342150A1 (en) 2017-11-30
EP2641601B8 (en) 2016-09-21
EP2641601B1 (en) 2016-07-06
CN101686971B (zh) 2013-09-11
PT2641601T (pt) 2016-10-14
HUS1600044I1 (hu) 2016-12-28
HRP20150449T1 (xx) 2015-06-05
EP2641600A1 (en) 2013-09-25
PT2068874E (pt) 2015-05-21
CY2016036I1 (el) 2017-07-12
EP2641601A1 (en) 2013-09-25
LTPA2016030I1 (lt) 2016-11-10
DK2068874T3 (da) 2015-04-27
NZ574978A (en) 2012-08-31
AU2007281684A1 (en) 2008-02-14
PL2641601T3 (pl) 2017-01-31
LTPA2016029I1 (lt) 2016-11-10
JP2010500371A (ja) 2010-01-07
ES2589302T3 (es) 2016-11-11
NL300840I2 (show.php) 2017-01-03
IL243933A0 (en) 2016-04-21
DK2641601T3 (en) 2016-08-22
LTPA2016031I1 (lt) 2016-11-10
LU93276I2 (fr) 2016-12-27
NO346835B1 (no) 2023-01-23
US20080152646A1 (en) 2008-06-26
HRP20161284T1 (hr) 2016-12-16
LTC2068874I2 (lt) 2018-11-12
EP2942057A1 (en) 2015-11-11
US20140322201A1 (en) 2014-10-30
WO2008019378A1 (en) 2008-02-14
CA2660356C (en) 2016-04-05
CN101686971A (zh) 2010-03-31
CA2660356A1 (en) 2008-02-14
SI2641601T1 (sl) 2016-11-30
AU2007281684B2 (en) 2013-05-16
HUS1600045I1 (hu) 2016-12-28
CY2016036I2 (el) 2017-07-12
LU93277I2 (fr) 2016-12-27

Similar Documents

Publication Publication Date Title
BRPI0716647A2 (pt) processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
BRPI0812288A2 (pt) Purificação de imunoglobulina.
NL1034256A1 (nl) Spectroscopiesysteem.
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
DE502007000819D1 (de) Abgasnachbehandlungssystem
NO344963B1 (no) Humanisert antistoff
DE502007005327D1 (de) Abgasnachbehandlungssystem
DK3401334T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
BRPI0717471A2 (pt) Dispositivo de entrada
DE502007000724D1 (de) Abgasnachbehandlungssystem
DE102007021985A8 (de) Fahrpedal-System
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme
DK2131841T3 (da) Fremgangsmåder til behandling af akut smerte
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
BRPI0718324A2 (pt) Métodos para o tratamento de depressão.
DE602007007552D1 (de) Multiprozessorsystem
DE602006013093D1 (de) Integriertes Übertragungssystem
ZA200903242B (en) Treatment for multiple myeloma
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
LU91233B1 (de) Laderaumsystem
BRPI0811781A2 (pt) Compostos de ((fenil) imidazolil)metilquinolinila terapêuticos.
BRPI0820437A2 (pt) Método de tratamento de artrite.
FI20060886A0 (fi) Prosessipesulaitteisto
ITCL20060032A1 (it) Progetto benessere

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DANA-FARBER CANCER INSTITUT, INC. (US) , FACET BIO

B25E Requested change of name of applicant rejected

Owner name: DANA-FARBER CANCER INSTITUT, INC. (US) , FACET BIO

B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.